The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Although the global bio sector index continues to be sluggish, we believe it will be important to pay close attention to global clinical trial data for ADC and KRAS inhibitors at 2022 ASCO (Jun 3~7).
An anti-AIDS drug candidate of the Korea Research Institute of Chemical Technology has been approved for sale in China. It is expected to become the first new drug candidate commercialized by the institute and the production in China is scheduled to start this year.This achievement was led by Dr. So
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Yuhan’s consolidated 2Q21 OP came to W23.4bn, exceeding consensus by 17%, with OP excluding licensing fees seeing a turn to profit. Serving as the main momentum driver are clinical trials for a Tagri
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Post-Covid-19 trend forecasts for the bio industry point to M&As and CMO momentum. With vaccine and diagnostic companies, backed by cash secured amid Covid-19, expected to be major M&A players, firms
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. With regards to Yuan’s Lazertinib, the two key issues for 2021 are to be: 1) phase II trial results for the SAVANNAH study; and 2) phase I brain metastasis data for the CHRYSALIS study. Yuhan is to r
The author is an analyst of Shinhan Investment Corp. He can be reached at shawn1225@shinhan.com. -- Ed. Gilead Sciences to acquire ADC developer ImmunomedicsGilead Sciences, according to the Wall Street Journal on September 12, will acquire antibody-drug conjugate (ADC) developer Immunomedics for US
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Focus on increased value of CD47 antibodiesOn Sep 4 (US time), China Biotech I-MAB (Nasdaq market cap of around W2tn) sealed a US$2bn licensing out deal (advance payment of US$200mn) granting the
The Ministry of Food and Drug Safety announced on Aug. 11 that 15 clinical trials are underway in South Korea in relation to COVID-19 and those are divided into 13 for treatment development and two for vaccine development. A total of 20 COVID-19 treatment and vaccine clinical trials have been approv
The authors are analysts of NH Investment & Securities. They can be reached at william.ku@nhqv.com and weihan@nhqv.com, respectively. – Ed. 1. Pay attention to newly-listed players displaying rapid progress in Covid-19 vaccine developmentNewly-listed biotech firms faring well amid pandemicThis year,
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. A large number of pharmaceutical/bio players, particularly testing kit companies, have been seeing earnings expansion amid the Covid-19 outbreak. With share prices of related treatment and vaccin
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. In addition to a clinical trial of Remdesivir that started in China in February, Gilead has launched additional global phase III clinical trials of the drug. Initial clinical trial results in Chi
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Affected by changes in accounting standards for the recognition of research progress, Yuhan’s 4Q19 licensing fee income was restrained to W3.3bn. But, we positively view a widening in margins tha
Boryung Pharmaceutical Co. announced on Aug. 27 that it has received approval for Phase 1 clinical studies on its anti-cancer therapy “BR2002” from the U.S. Food and Drug Administration (FDA). The Phase 1 clinical trial will be conducted on 90 patients with non-Hodgkin's lymphoma tumors. It is d
A considerable number of Korean biotech ventures are shifting the focus of their new drug development efforts from technology exports to phase-3 clinical trials following SillaJen’s aborted global phase 3 clinical trial for its highly anticipated liver cancer treatment.Sillajen announced on Aug. 4 t
Yuhan Co. announced on Jan. 7 that it has licensed out a new nonalcoholic steatohepatitis (NASH) drug candidate to Gilead Sciences, a global pharmaceutical company known for its product Tamiflu, for US$785 million.Yuhan will receive a down payment of US$15 million (16.7 billion won) from Gilead. Yuh
The Korean biotech industry joined competition to develop a chimeric antigen receptor-T cell (CAR-T) therapeutic drug called “the cancer drug of doctors’ dream.” CAR-T is a technology that allows T cells which are a kind of common immune cells in blood to selectively attack cancer cells after pinpoi
Donald Trump, who pledged the abolition of “Obama Care” that encourages all American people to join a government-led national health insurance program and use medicines at lower prices, was elected as 45th president of the United States, casting dark clouds over Korea's bio and pharmaceutical indust
It has been found that Hanmi Pharm recorded 216.5 billion won in outpatient prescription in South Korea in the first half of this year to top the list. Pfizer Pharmaceuticals Korea, which ranked first last year with 389.8 billion won, took the second place in the first half with 213.9 billion won.In
NH Investment & Securities on Feb. 26 said that the Yuhan Corporation became the first domestic pharmaceutical company to surpass 1 trillion won (US$913.24 million) in sales last year and will see the steady sales growth this year, maintaining its target stock prices at 230,000 won (US$210.05) wit